吉利德TROP-2 ADC一线治疗三阴性乳腺癌III期研究再获成功

医药魔方
24 May

5月23日,吉利德宣布了III期ASCENT-03研究取得了积极结果。该研究达到了主要终点,与化疗相比,Trodelvy(戈沙妥珠单抗)在不适合接受PD-1/PD-L1抑制剂治疗(即PD-L1阴性或无法接受免疫治疗)的一线转移性三阴性乳腺癌(mTNBC)患者中,显示出高度显著且具有临床意义的无进展生存期(PFS)改善。Trodelvy是一种first-in-class的靶向TROP-2的ADC。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10